Impact of the Epidemic of COVID-19 Infection Among People Living With HIV (SARS-CoV-2)

Not Applicable

• Conditions: Covid19; Virus-HIV
• Interventions: Other: questionnaire

• Registration Number: NCT04581746
• Lead Sponsor: Tourcoing Hospital

Brief Summary

The non-essential and non-urgent follow-up consultations of patients living with HIV were postponed or transformed into "teleconsultation" or exchanges of e-mails between practitioners and patients during COVID-19 epidemic. This change in care can have an impact on follow-up and access to treatment for PVVIH.

Detailed Description

On 16 March 2020, an instruction to postpone "non-urgent" consultations was given to doctors. Thus, the non-essential and non-urgent follow-up consultations of patients living with HIV were postponed or transformed into "teleconsultation" or exchanges of e-mails between practitioners and patients. This change in care can have an impact on follow-up and access to treatment for PVVIH. In addition, the epidemic itself may have consequences: PVVIH may be at greater risk because of their immunosuppression and associated co-morbidities.

Study Timeline

• Study First Submitted: 2020-09-22
• Study First Submitted QC: 2020-10-07
• Study First Posted: 2020-10-09
• Study Start: 2020-11-25
• Status Verified: 2022-05
• Last Update Submitted: 2022-05-09
• Last Update Posted: 2022-05-10
• Primary Completion: 2022-06
• Study Completion: 2022-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 1800

Inclusion Criteria

• Patient followed up for HIV infection in one of the COREVIH Hauts de France centres participating in the study
• Having communicated an email address
• Having given their consent to participate in this study
• Beneficiary subject affiliated or entitled to a social security scheme

Exclusion Criteria

• Minor patient
• Refusal to participate
• Patient under guardianship

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
experimental arm	questionnaire	questionnaire and follow-up visit

Primary Outcome Measures

Name	Time	Method
Prevalence of SARS CoV2 infection in PVVIH in Hauts de France	Inclusion	Determination of the number of patients with microbiologically or clinically-biologically proven SARS CoV2 infection at inclusion in the study

Secondary Outcome Measures

Name	Time	Method
Prevalence of SARS CoV2 infection in PVVIH in Hauts de France	through study completion, an average of 19 months	Determination of the number of patients with microbiologically or clinically-biologically proven SARS CoV2 infection at the end of the study
Determine the incidence rate of COVID 19 among PVVIH antiretroviral treatment	through study completion, an average of 19 months	Percentage of patients who stopped their antiretroviral treatment
Determine the incidence rate of COVID 19 among PVVIH discontinuing antiretroviral treatment	through study completion, an average of 19 months	Reason for discontinuing antiretroviral treatment
Determine the incidence rate of COVID 19 among PVVIH who stopped all follow-up	through study completion, an average of 19 months	Percentage of patients who stopped all follow-up by an infectious disease specialist
Psychological consequences of this epidemic among PVVIH : HAD	through study completion, an average of 19 months	Evaluation of the psychological scales HAD on PVVIH
Psychological consequences of this epidemic among PVVIH : PROQOL-HIV	through study completion, an average of 19 months	Evaluation of the psychological scales PROQOL-HIV on PVVIH

Trial Locations

Locations (3)

CHU Amiens Picardie; 🇫🇷 Amiens, France

CH Lens; 🇫🇷 Lens, France

CH Tourcoing; 🇫🇷 Tourcoing, France